Naloxone as an adjuvant to bupivacaine in intrapleural infiltration

Small dose of naloxone as an adjuvant to bupivacaine in intrapleural infiltration after thoracotomy surgery; prospective, control study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201805003370384

Enrollment

Registered

2018-05-04

Start date

2018-05-05

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Surgery postoperative pain after thoracotomy

Interventions

bupivacaine- naloxone group

bupivacaine group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 60 patients of either sex, ASA I &II, 18-60 years, scheduled to undergoing unilateral thoracic surgery (diaphragmatic hernia repair, lymph node excision, decortication and pneumonectomy)

Exclusion criteria

Exclusion criteria: Emergency operations, previous thoracotomy, allergy to local anesthetics (LAs), previous unusual response or complications related to anesthesia, pre-existing coagulopathy, sever comorbidity, patients with a history of pleuritis, history of traumatic or spontaneous pneumothorax, haemothorax, or pneumonia or another condition responsible for a potential increase in absorption of local anaesthetic, cardiac failure, known upper airway obstruction or apnoeic attacks and local infection

Design outcomes

Primary

Measure	Time frame
the time for the first request for rescue analgesia	—

Secondary

Measure	Time frame
the severity of postoperative pain	—

Countries

Egypt

Contacts

Public Contactnada Omara

assistant lecturer of phonetics

Dr.nada.emera@gmail.com01118342012

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026